Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 6/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127529 | 0.85 | RIPK2 (0.46) | RIPK2FYNEGFRLMNAKDM4E | |
| SCHEMBL7128686 | 0.80 | RIPK2 (0.47) | RIPK2CD38EGFRLMNAKDM4E | |
| SCHEMBL7119187 | 0.78 | FYN (0.45) | RIPK2WNT1FYNLMNATTK | |
| SCHEMBL7130667 | 0.77 | PIP4K2A (0.38) | RIPK2RIPK3EGFRKDM4EAURKB | |
| SCHEMBL7128055 | 0.75 | NR2E1 (0.39) | RIPK2RIPK3EGFRAURKBHTT | |
| SCHEMBL7117284 | 0.75 | JUN (0.38) | RIPK2RIPK3EGFRAURKBHTT | |
| SCHEMBL7120883 | 0.74 | RIPK2 (0.42) | RIPK2FYNEGFRLMNAKDM4E | |
| SCHEMBL7119935 | 0.74 | RIPK2 (0.41) | RIPK2FYNTTK | |
| SCHEMBL7120246 | 0.73 | FYN (0.47) | FYNKDM4EHTT | |
| SCHEMBL7127426 | 0.72 | RIPK2 (0.44) | RIPK2EGFRLMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | RIPK2 3457/4885RIPK3 3604/4885WNT1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.